Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 5.5% - Here's What Happened

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s share price traded up 5.5% during mid-day trading on Thursday . The stock traded as high as $12.71 and last traded at $13.08. 11,501 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 454,296 shares. The stock had previously closed at $12.40.

Analyst Ratings Changes

A number of equities analysts have recently commented on BCAX shares. HC Wainwright raised their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, January 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, Wedbush reissued an "outperform" rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $36.50.

Bicara Therapeutics Price Performance

The company has a 50 day simple moving average of $12.96.

Institutional Trading of Bicara Therapeutics

Several hedge funds have recently modified their holdings of the company. California State Teachers Retirement System bought a new position in shares of Bicara Therapeutics during the 4th quarter worth approximately $25,000. Spire Wealth Management acquired a new position in shares of Bicara Therapeutics during the fourth quarter worth $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $32,000. Legal & General Group Plc acquired a new stake in shares of Bicara Therapeutics in the 4th quarter worth $33,000. Finally, Summit Investment Advisors Inc. purchased a new position in Bicara Therapeutics during the 4th quarter worth $35,000.

Remove Ads

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.